Small Molecule Inhibitors of the Mitochondrial Permeability Transition Pore (PTP)

Case ID:
Web Published:

Compositions for Treatment of Neurological and Oxidative Stress Disorders

Researchers at Oregon Health & Science University and Kansas University discovered novel small molecule inhibitors of mitochondrial permeability transition pore (mtPTP) for treatment of cellular disorders associated with an over-accumulation of mitochondrial calcium or reactive oxygen species. Compounds in this class are the most potent mtPTP inhibitors known and are useful for therapeutically challenging human diseases, such as, multiple sclerosis (MS), amyotropic lateral sclerosis (ALS), Alzheimer's disease (AD), muscular dystrophies (MDs), type II diabetes, heart infarction, and stroke.

Technology 1967 is available for exclusive licensing and/or collaborative co-development.

Patent Status: Provisional patent application filed.

If interested in learning more, please contact Travis Cook ( and reference Tech Id No. 1967. OHSU Investigators: Dennis Bourdette, MD; Michael Forte, Ph.D.

Patent Information:
For Information, Contact:
Travis Cook
Senior Technology Development Manager
Oregon Health & Science University
Michael Forte
Dennis Bourdette
Paolo Bernardi
Justina Sileikyte
Frank Schoenen
Sudeshna Roy
Therapeutics - Cardiology
Therapeutics - Neurology
© 2019. All Rights Reserved. Powered by Inteum